Shaken By Recall Of Claris' IV Products, Pfizer Puts Brakes On Vials Too; Vows To Ensure Patient Safety
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Faced with an undesirable ordeal of a nationwide recall of metronidazole, ciprofloxacin and ondansetron in the United States - the three intravenous hospital products sourced from its Indian partner Claris Lifesciences - the world's largest pharma company Pfizer has decided to stop distribution of the vial forms of the drug "out of abundance of caution.